What changed: Diffuse midline glioma, H3 K27-altered (including DIPG)
Every dated change on the records linked to Diffuse midline glioma, H3 K27-altered (including DIPG), newest first: approvals and regulatory steps on its medicines, trials that reported, guideline versions, milestones, and when this page itself was checked. Dates come from the records; none is inferred. Orientation, not medical advice.
September 2026 · 1
2025 · 2
- 2025GuidelineDiffuse midline glioma, H3 K27-altered (including DIPG)Guideline FDA accelerated approval, 6 August 2025: Progressive after radiotherapy, H3 K27M-mutant
Dordaviprone (ONC201), FDA accelerated approval August 2025 for patients aged one year and older with progressive disease; re-irradiation is an alternative or addition.
- 2025MilestoneDordaviproneDordaviprone approved
FDA accelerated approval on 6 August 2025 for progressive H3 K27M-mutant diffuse midline glioma, the first systemic therapy for the disease.
2024 · 1
2022 · 2
- 2022Trial resultNCI-COG Pediatric MATCH (APEC1621)NCI-COG Pediatric MATCH (APEC1621) reported
Actionable alteration in 31.
- 2022MilestoneCAR-T for glioma (IL13Rα2, GD2, EGFRvIII, multi-target)First GD2 CAR-T responses in patients
Majzner and colleagues (Nature) report clinical and radiographic improvement with intravenous then intracerebroventricular dosing.